US Bancorp DE Sells 2,107 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)

US Bancorp DE trimmed its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 1.6% in the fourth quarter, Holdings Channel reports. The firm owned 131,019 shares of the company’s stock after selling 2,107 shares during the quarter. US Bancorp DE’s holdings in Axsome Therapeutics were worth $11,086,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of AXSM. R Squared Ltd acquired a new stake in shares of Axsome Therapeutics in the fourth quarter valued at approximately $64,000. KBC Group NV lifted its position in shares of Axsome Therapeutics by 40.5% in the fourth quarter. KBC Group NV now owns 1,336 shares of the company’s stock valued at $113,000 after buying an additional 385 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Axsome Therapeutics by 22.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company’s stock valued at $156,000 after buying an additional 318 shares during the last quarter. Moors & Cabot Inc. acquired a new stake in shares of Axsome Therapeutics in the third quarter valued at approximately $200,000. Finally, Whalen Wealth Management Inc. acquired a new stake in shares of Axsome Therapeutics in the third quarter valued at approximately $236,000. 81.49% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CFO Nick Pizzie sold 3,000 shares of Axsome Therapeutics stock in a transaction on Friday, February 14th. The stock was sold at an average price of $131.07, for a total value of $393,210.00. Following the transaction, the chief financial officer now owns 42,187 shares in the company, valued at approximately $5,529,450.09. This trade represents a 6.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 22.40% of the company’s stock.

Axsome Therapeutics Price Performance

Shares of NASDAQ AXSM opened at $127.15 on Tuesday. The stock has a market capitalization of $6.20 billion, a PE ratio of -21.23 and a beta of 1.05. The company has a debt-to-equity ratio of 3.22, a current ratio of 2.11 and a quick ratio of 2.04. The business has a fifty day moving average price of $105.81 and a two-hundred day moving average price of $96.81. Axsome Therapeutics, Inc. has a fifty-two week low of $64.11 and a fifty-two week high of $139.13.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) earnings per share for the quarter, beating the consensus estimate of ($0.97) by $0.01. The firm had revenue of $118.77 million during the quarter, compared to analysts’ expectations of $117.83 million. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. As a group, equities analysts predict that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on AXSM. Morgan Stanley raised their price objective on Axsome Therapeutics from $125.00 to $190.00 and gave the company an “overweight” rating in a research report on Thursday, February 27th. William Blair reissued an “outperform” rating on shares of Axsome Therapeutics in a report on Tuesday, February 18th. Leerink Partners lifted their price target on Axsome Therapeutics from $110.00 to $150.00 and gave the stock an “outperform” rating in a report on Monday, February 10th. Needham & Company LLC reissued a “buy” rating and set a $153.00 price target on shares of Axsome Therapeutics in a report on Monday. Finally, Wells Fargo & Company lifted their price target on Axsome Therapeutics from $140.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. One equities research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $167.36.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.